What is the recommended intravenous acyclovir dose and duration for treating viral meningitis in adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Acyclovir Dosing for Viral Meningitis

For viral meningitis specifically (not encephalitis), the evidence does not support routine use of acyclovir, as most viral meningitis is self-limited and caused by enteroviruses that do not respond to acyclovir. However, when HSV or VZV meningitis is suspected or confirmed, treatment is warranted with specific dosing regimens.

Key Distinction: Meningitis vs. Encephalitis

The provided guidelines primarily address viral encephalitis, not isolated viral meningitis 1, 2, 3. This is a critical distinction because:

  • Viral meningitis (inflammation of meninges only) is typically benign and self-limited
  • Viral encephalitis (brain parenchyma involvement) carries 20-30% mortality even with treatment and requires aggressive antiviral therapy 1

The decision to treat depends on whether there is encephalitis (altered mental status, focal neurological signs, seizures) or isolated meningitis (headache, fever, meningismus only).

When to Treat Viral Meningitis with Acyclovir

Definite Indications:

  • HSV-2 meningitis with severe symptoms or immunocompromised status
  • VZV meningitis with any of: encephalitis features, myelitis, ≥3 dermatomes involved, immunosuppression 4
  • Cannot exclude encephalitis clinically (altered consciousness, confusion, focal signs)

Questionable/No Clear Indication:

  • Isolated HSV-2 meningitis in immunocompetent patients often resolves without treatment 5, 6, 7, 4
  • Recent data shows many patients with VZV DNA in CSF and isolated meningitis receive acyclovir unnecessarily, with high rates of acute kidney injury (37%) 4

Dosing Regimens

For HSV Meningitis (when treatment indicated):

Adults:

  • 10 mg/kg IV every 8 hours 3, 8
  • Duration: 14-21 days for encephalitis 1, 3, 1
  • For isolated meningitis: Shorter courses (3-10 days) may be adequate 5, 9, 6

Children:

  • Age 3 months-12 years: 500 mg/m² IV every 8 hours 1
  • Age >12 years: 10 mg/kg IV every 8 hours 1
  • Neonates with CNS disease: 20 mg/kg IV every 8 hours for 21 days 10, 3
  • Duration for children: Minimum 14-21 days (21 days preferred for ages 3 months-12 years due to higher relapse rates up to 29%) 1

For VZV Meningitis (when treatment indicated):

Adults:

  • 10 mg/kg IV every 8 hours (some recommend 10-15 mg/kg if renal function normal) 2
  • Duration: Up to 14 days 2

Children:

  • Same weight-based dosing as HSV above 1

Critical Safety Considerations

Renal Toxicity:

  • Acyclovir causes reversible nephropathy in up to 20% of patients, typically after 4 days of therapy 1
  • Must infuse over at least 1 hour to reduce renal tubular damage 8
  • Maintain adequate hydration and monitor renal function closely 1
  • Dose reduction required for pre-existing renal impairment 1, 8

Dosing Adjustments for Renal Impairment:

Based on creatinine clearance 8:

  • CrCl >80: Standard dosing
  • CrCl 50-80: Reduce frequency or dose
  • CrCl 15-50: Further reduction needed
  • CrCl 0 (anuric): Half-life increases from 2.5 to 19.5 hours—significant dose reduction essential

Treatment Duration and Monitoring

For Proven HSV Encephalitis (not isolated meningitis):

  • 14-21 days minimum 1
  • Consider repeat LP at 14-21 days to confirm CSF HSV PCR negativity 1
  • If CSF still positive: continue acyclovir with weekly CSF PCR until negative 1
  • Children 3 months-12 years: minimum 21 days before repeat LP 1

For Isolated HSV-2 Meningitis:

  • Evidence suggests shorter courses (3-10 days IV) may be adequate 5, 9
  • Some patients treated with low-dose acyclovir (15 mg/kg/day total) for 10 days had complete resolution 6
  • Oral valacyclovir (500 mg-1g twice daily for 5-14 days) used in some cases after initial IV therapy 5, 9

Common Pitfalls to Avoid

  1. Over-treatment of benign viral meningitis: Most viral meningitis (enteroviral) doesn't require or respond to acyclovir. Don't reflexively treat all "viral meningitis" 4

  2. Under-dosing or short duration in true encephalitis: If encephalitis is present, inadequate treatment (<14 days) increases relapse risk to 26-29% in children 1

  3. Ignoring renal function: Failure to adjust dose or monitor renal function leads to preventable nephrotoxicity in 20% of patients 1

  4. Delaying treatment when encephalitis possible: If you cannot exclude encephalitis, start acyclovir within 6 hours while awaiting diagnostics 1. Delays >48 hours worsen outcomes 1

  5. Stopping acyclovir prematurely based on negative initial CSF PCR: In true HSV encephalitis, CSF PCR remains positive for 7-10 days even after starting treatment 1

Practical Algorithm

Step 1: Determine if this is isolated meningitis or possible encephalitis

  • Altered mental status, confusion, focal signs, seizures → Treat as encephalitis
  • Only headache, fever, meningismus → Consider observation if immunocompetent

Step 2: If treating, use appropriate dose:

  • Adults: 10 mg/kg IV q8h
  • Children >12 years: 10 mg/kg IV q8h
  • Children 3 months-12 years: 500 mg/m² IV q8h
  • Neonates with CNS disease: 20 mg/kg IV q8h

Step 3: Duration based on diagnosis:

  • Encephalitis confirmed: 14-21 days (21 days for young children)
  • Isolated meningitis: 7-14 days may suffice
  • Repeat LP at end of therapy if poor response

Step 4: Monitor renal function every 2-3 days and adjust dose accordingly

References

Research

Low-dose acyclovir for HSV-2 meningitis in a child.

Acta paediatrica (Oslo, Norway : 1992), 2004

Research

[Herpes simplex virus meningitis in 11 patients].

Medecine et maladies infectieuses, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.